4:24 PM
 | 
May 07, 2014
 |  BC Extra  |  Company News

J&J looks to expand Olysio label to include use with Sovaldi

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) submitted an sNDA to FDA to expand the label of Olysio simeprevir to include its use in combination with Sovaldi sofosbuvir from

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >